All News
ACR Best Abstracts - Day 2
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for #ACRbest abstracts today:
Can Neural Networks Answer Important Diagnostic Dilemmas in Rheumatology?
An interesting study presented at ACR22 looked at whether neural networks can distinguish seropositive rheumatoid arthritis (RA+), seronegative RA (RA-), and psoriatic arthritis (PsA) using hand MRI data based on the structural inflammation patterns.
Read Article
DAVIX is a promising surrogate outcome measure of vascular disease in SSc. Questions around cost and access remain. Abs 1541 #ACR22 @RheumNow https://t.co/KJgtcG5ah8 https://t.co/NsK7b8fQFt
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow video from #ACR22
Opioid use in PsA and SpA patients
Discussing abstract 1012 by @AlexisOgdie
https://t.co/fKRog1aIkH
Eric Dein ericdeinmd ( View Tweet)
Out work showing JIA pts with sharp decline in needing TKAs, however increased TKA utilizations for tumors!! We are treating inflammatory arthritis better over timein the pediatric population...Natiowide data over 15 years! #ACR22 @Rheumnow abst# 0843 https://t.co/inw41Y1o9r
Bella Mehta bella_mehta ( View Tweet)
TONIGHT! Join us! #ACR22
https://t.co/P0HHEl19hH https://t.co/zjfoNrlYGk
Links:
Dr. John Cush RheumNow ( View Tweet)
One of my personal highlights. History lesson with intersection of medicine. The hilarious @adamjbrown
@RheumNow #ACR22 #rheuminations #factsperminute https://t.co/vDoKLsVfhB
Julian Segan JulianSegan ( View Tweet)
Abst0327 #ACR22 SMART-SLE Monitoring
Some SLE patients with +dsDNA have persistent positivity, others have fluctuations
Anti-dsDNA in persistently positive HR 1.56 for flare risk
Change (up or down!) in dsDNA more than 2x prior visit for fluctuating patients: HR 1.43
@RheumNow https://t.co/YwDPTYWPLu
Eric Dein ericdeinmd ( View Tweet)
Abst0324 #ACR22
How close are we to measuring Interferon Signature in clinical practice?
NCounter and BioFire assays studied - correlated well we each other
Genes: IFI27, IFI44L, IFIT1, RSAD2
SLE higher than RA or FMS, but does not correlate with SLE activity
@RheumNow https://t.co/izpFtj9Pcd
Eric Dein ericdeinmd ( View Tweet)
Abst0326 #ACR22 Anti-Mitochondrial Ab in SLE
Whole mitochondrial (AwMA), AmtDNA or AmtRNA - higher in SLE compared to controls
AwMA predictive of death, AmtDNA and AmtRNA predictive of nephritis
@Rheumnow https://t.co/d98HSHnJVE
Eric Dein ericdeinmd ( View Tweet)
Abst0328 #ACR22. Predicting UCTD to CTD Meta-Analysis
Factors for SLE transition: younger age, serositis, dsDNA
SSc transition: puffy finger, NFC, or SSc antibodies
No studies wo moderate or high risk of bias
Limited studies on biomarkers for SLE, need more studies
@Rheumnow https://t.co/GofGF8TkCx
Eric Dein ericdeinmd ( View Tweet)
All monster stories end with an unexpected award: A new order
@cuttingforstone at #ACR22 tells the monster story of #covid
“How will history review our story?”
The science will get an A+, but we failed to learn the lessons of history
All was predictable through history
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Year in Review #ACR22
GLORIA
Low steroid usage: lower DAS28, reduced joint damage
BUT 24% increased adverse effects
@RheumNow https://t.co/vYTAhoQEqr
Eric Dein ericdeinmd ( View Tweet)
Ab1012 #ACR22
@AlexisOgdie Opioid Use & Healthcare Utilization in PsA and AS
21% PsA pts on opioids, 27% AS on opioids
Opioid users - more co-morbidities, 🚬, worse disease
Tended to higher use of anti-rheumatic drugs
Higher health care utilizations, medical $$
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
@RheumNow Panel felt that weight and smoking recs were adequately covered by general health recommendations
BUT, this misses a HUGE opportunity to stress that inflammatory arthritis pts have higher risks and need greater emphasis on modifiable risk factors than gen pop
#ACR22 @RheumNow
Eric Dein ericdeinmd ( View Tweet)
CASIPSA results: CT SIJ characteristics from PsA pts similar to age- and sex-matched controls, but w/ higher prevalence of erosions, found in 18% of PsA patients. Abs 1012 #ACR22 https://t.co/jdUSUoUUbf https://t.co/2NQOhncYFc
Dr. Rachel Tate uptoTate ( View Tweet)
Look at these graphs and try and tell me that sex and gender doesn't matter in RA.
We have seen in study after study after study - sex and gender matters.
ABST0241 @erasmusmcintl #ACR22 @RheumNow https://t.co/GQnKrAp0eB https://t.co/MxHRy2kwDN
David Liew drdavidliew ( View Tweet)
New IgG4-RD therapeutic avenues,
mechanistically driven (B cell-CTL interaction):
inebilizumab: registered for NMO, ph3 now
obexelimab: novel dual MOA ?safer, ph3 now
rilzabrutinib: BTKi, ph2 now
elotuzumab: targets SLAMF7, MM registered, NIH study
John Stone #ACR22 @RheumNow https://t.co/lx4bnCutlS
David Liew drdavidliew ( View Tweet)
Pre-RA studies: a summary by Dr. Deane #ACR22 @RheumNow https://t.co/HU8JWmYM8H
David Liew drdavidliew ( View Tweet)
One of the nicest, smartest, and hardest working young rheumatologists you will meet, and I'm sure is destined for great things. My hat off to you @SattuiSEMD, congratulations!
#ACR22 @RheumNow https://t.co/dzHXeahsHT
David Liew drdavidliew ( View Tweet)